Ticker

NEW YORK, April 16, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ICU Medical, Inc. (NASDAQ: ICUI) on behalf of the company's shareholders.  The investigation seeks to determine whether ICU Medical's directors breached their fiduciary duties in connection with recent corporate actions.

ICU Medical (NASDAQ: ICUI) executives highlighted the company's evolution into what CEO Vivek Jain described as "the world's only pure-play infusion company" during a fireside chat at the 25th Annual Needham Healthcare Conference, while also addressing pricing dynamics, product roadmaps, macro pressures, and capital allocation priorities. Company evolution and investment positioning Jain said ICU Medical has

ICU Medical is positioned for margin expansion as Smiths Medical integration and remediation costs subside, with upcoming product launches supporting growth. ICUI is gaining share in infusion pumps and consumables, leveraging product differentiation and rebounding from past compliance issues. Management targets net debt/EBITDA below 2.0x, opening the door for increased capital returns via buybacks or dividends…

Sanara MedTech (NASDAQ: SMTI - Get Free Report) and ICU Medical (NASDAQ: ICUI - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation. Insider and Institutional Ownership 8.1% of Sanara MedTech

NEW YORK, March 25, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ICU Medical, Inc. (NASDAQ: ICUI) on behalf of the company's shareholders.  The investigation seeks to determine whether ICU Medical's directors breached their fiduciary duties in connection with recent corporate actions.